• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    CAS No. 10540-29-1 Price
    Catalog No.CFN93321Purity>=98%
    Molecular Weight371.51Type of CompoundXanthones
    FormulaC26H29NOPhysical DescriptionPowder
    Download     COA    MSDSSimilar structuralComparison (Web)
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    Our products had been exported to the following research institutions and universities, And still growing.
  • University of Illinois at Chicago (USA)
  • Shanghai Institute of Organic Ch... (China)
  • Northeast Normal University Chan... (China)
  • Universidad Industrial de Santan... (Colombia)
  • Johannes Gutenberg University Ma... (Germany)
  • Universita' Degli Studi Di Cagli... (Italy)
  • Chinese University of Hong Kong (China)
  • Monash University Malaysia (Malaysia)
  • Worcester Polytechnic Institute (USA)
  • Molecular Biology Institute of B... (Spain)
  • Universiti Kebangsaan Malaysia (Malaysia)
  • More...
  • Package
    Featured Products

    Catalog No: CFN99282
    CAS No: 118-34-3
    Price: $90/20mg
    5-O-Feruloylquinic acid

    Catalog No: CFN92889
    CAS No: 40242-06-6
    Price: $448/5mg
    Ginsenoside Rg5

    Catalog No: CFN92643
    CAS No: 186763-78-0
    Price: $168/10mg

    Catalog No: CFN95001
    CAS No: 1891-25-4
    Price: $358/5mg
    Salvianolic acid B

    Catalog No: CFN99332
    CAS No: 115939-25-8
    Price: $80/20mg
    Tamoxifen Description
    Biological Activity or Inhibitors: 1. Tamoxifen acts as an estrogen agonist by preventing the skeletal alterations that result from ovarian hormone deficiency.
    2. Tamoxifen is currently the first-line therapy for treatment of hormone-dependent breast cancer.
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds
    5-O-Feruloylquinic acid

    Catalog No: CFN92889
    CAS No: 40242-06-6
    Price: $448/5mg

    Catalog No: CFN95003
    CAS No: N/A
    Price: $358/5mg

    Catalog No: CFN92179
    CAS No: 67656-29-5
    Price: $338/5mg

    Catalog No: CFN92855
    CAS No: 2196-14-7
    Price: $100/5mg

    Catalog No: CFN95030
    CAS No: 941269-84-7
    Price: $368/5mg
    Epimedoside A

    Catalog No: CFN90762
    CAS No: 39012-04-9
    Price: $198/10mg
    Columbianetin beta-D-glucopyranosi...

    Catalog No: CFN95038
    CAS No: 55836-35-6
    Price: $288/5mg
    Magnolignan C

    Catalog No: CFN96189
    CAS No: 93697-42-8
    Price: $413/5mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    Scientific Reports 2017 Dec 11;7(1):17332.
    doi: 10.1038/s41598-017-17427-6.

    PMID: 29230013

    Molecules. 2017 Oct 27;22(11). pii: E1829.
    doi: 10.3390/molecules22111829.

    PMID: 29077044

    J Cell Biochem. 2018 Feb;119(2):2231-2239.
    doi: 10.1002/jcb.26385.

    PMID: 28857247

    Phytomedicine. 2018 Feb 1;40:37-47.

    PMID: 29496173
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 2.6917 mL 13.4586 mL 26.9172 mL 53.8344 mL 67.2929 mL
    5 mM 0.5383 mL 2.6917 mL 5.3834 mL 10.7669 mL 13.4586 mL
    10 mM 0.2692 mL 1.3459 mL 2.6917 mL 5.3834 mL 6.7293 mL
    50 mM 0.0538 mL 0.2692 mL 0.5383 mL 1.0767 mL 1.3459 mL
    100 mM 0.0269 mL 0.1346 mL 0.2692 mL 0.5383 mL 0.6729 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Tamoxifen References Information
    Citation [1]

    J Bone Miner Res. 1987 Oct;2(5):449-56.

    Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats.[Pubmed: 3455628 ]
    Tamoxifen increased the serum calcium and phosphate by itself and did not change serum 1,25-dihydroxyvitamin D in ovariectomized rats. Ovariectomy produced significant increases in medullary area, periosteal bone formation rate, and periosteal bone apposition rate compared to values in sham-operated animals and did not change endosteal bone formation rate. The increase in medullary area resulted from an increase in osteoclast number and resorbing surface length. Although endosteal forming surface length decreased, this was compensated for by an increase in the apposition rate. 17 beta-estradiol and Tamoxifen each prevented the increases in bone formation rate and medullary area in ovariectomized rats. Tamoxifen reduced the length of the resorbing surface and osteoclast number to values observed in sham-operated animals. The findings demonstrate that in the rat, Tamoxifen acts as an estrogen agonist by preventing the skeletal alterations that result from ovarian hormone deficiency.
    Citation [2]

    Cancer Res. 1999 Nov 1;59(21):5421-4.

    Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients.[Pubmed: 10554009]
    Tamoxifen is currently the first-line therapy for treatment of hormone-dependent breast cancer. However, despite initial benefits, most patients eventually relapse. Two groups of patients were identified: (a) a Tamoxifen-sensitive group (n = 8); and (b) a Tamoxifen-resistant group (n = 9). Using reverse transcription-PCR, the relative expression of mRNA for both estrogen receptor (ER) beta and transforming growth factor beta1 was determined in each patient group and quantified against a known reference standard. ER-beta mRNA was significantly up-regulated in the Tamoxifen-resistant group as compared with the Tamoxifen-sensitive group (P = 0.001 by Fisher's exact test), and, consistent with previous findings, transforming growth factor beta1 was also up-regulated in the Tamoxifen-resistant cohort (P = 0.02). The importance of ER-beta in Tamoxifen resistance was validated using Tamoxifen-sensitive and -resistant cell lines, in which it was demonstrated that ER-beta mRNA was significantly up-regulated in the resistant cells. These results lend further support to a role for ER-beta as a poor prognostic factor in breast cancer.